(Q43250891)

17 November 2017

title

Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway (English)

1 reference

17 November 2017

B Markova

1

1 reference

17 November 2017

C Albers

2

1 reference

17 November 2017

F Breitenbuecher

3

1 reference

17 November 2017

J V Melo

4

1 reference

17 November 2017

T H Brümmendorf

5

1 reference

17 November 2017

F Heidel

6

1 reference

17 November 2017

D Lipka

7

1 reference

17 November 2017

J Duyster

8

1 reference

17 November 2017

C Huber

9

1 reference

17 November 2017

T Fischer

10

1 reference

17 November 2017

language of work or name

English

0 references

publication date

2 November 2009

1 reference

17 November 2017

1 reference

17 November 2017

volume

29

1 reference

17 November 2017

issue

5

1 reference

17 November 2017

page(s)

739-751

1 reference

Inhibitory effect of imatinib on normal progenitor cells in vitro

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

21 January 2018

mTOR and cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Mammalian target of rapamycin as a therapeutic target in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

PDGF stimulation of inositol phospholipid hydrolysis requires PLC-gamma 1 phosphorylation on tyrosine residues 783 and 1254.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Absence of erythrogenesis and vasculogenesis in Plcg1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Role of class II phosphoinositide 3-kinase in cell signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Chronic myeloid leukaemia: stem cell derived but progenitor cell driven

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Regulation of phosphoinositide-specific phospholipase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

PI3-kinase and TOR: PIKTORing cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Abl: the prototype of oncogenic fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Growing roles for the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Studying the pathogenesis of BCR-ABL+ leukemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Regulation of phospholipase C gamma isoforms in haematopoietic cells: why one, not the other?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

The mammalian target of rapamycin-p70 ribosomal S6 kinase but not phosphatidylinositol 3-kinase-Akt signaling is responsible for fibroblast growth factor-9-induced cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

AKT-independent phosphorylation of TSC2 and activation of mTOR and ribosomal protein S6 kinase signaling by prostaglandin F2alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Phosphoinositide 3-kinase-dependent regulation of phospholipase Cgamma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Phosphoinositide 3-kinase regulates phospholipase Cgamma-mediated calcium signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.374

31 March 2020

Identifiers

DOI

10.1038/ONC.2009.374

1 reference

Dimensions Publication ID

17 November 2017

1021833798

0 references

1 reference